{"id":869967,"date":"2025-07-15T17:29:14","date_gmt":"2025-07-15T21:29:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/"},"modified":"2025-07-15T17:29:14","modified_gmt":"2025-07-15T21:29:14","slug":"attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/","title":{"rendered":"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">PHILADELPHIA<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4468695-1&amp;h=1386673486&amp;u=https%3A%2F%2Fbergermontague.com%2F&amp;a=Berger+Montague+PC\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Berger Montague PC<\/span><\/a><\/u>, a nationally recognized securities litigation firm based in <span class=\"xn-location\">Philadelphia<\/span>, announces it is investigating a newly filed securities class action lawsuit against <b>Rocket Pharmaceuticals, Inc.<\/b><b>(NASDAQ: RCKT) <\/b>(&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;). The case was filed in the U.S. District Court for the District of <span class=\"xn-location\">New Jersey<\/span> and <span>alleges<\/span> that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" title=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" alt=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, <span class=\"xn-location\">New Jersey<\/span>, is a biotechnology company focused on developing gene therapies for rare diseases.<\/p>\n<p>The suit <span>alleges<\/span> that the Company failed to inform investors of a substantial protocol change, specifically the addition of a novel immunomodulatory agent, prior to a serious adverse event (SAE) and subsequent FDA clinical hold. Following the Company&#8217;s disclosure of a patient death in the trial, RCKT shares fell nearly 37%, from <span class=\"xn-money\">$6.27<\/span> on <span class=\"xn-chron\">May 23, 2025<\/span>, to <span class=\"xn-money\">$2.33<\/span> on <span class=\"xn-chron\">May 27, 2025<\/span>.<\/p>\n<p>\n        <b><br \/>\n          <i>Investor Deadline: <\/i><br \/>\n        <\/b><br \/>\n        <i>Investors who purchased Rocket Pharmaceuticals securities between <b><span class=\"xn-chron\">February 27, 2025<\/span> and <span class=\"xn-chron\">May 26, 2025<\/span><\/b> (the &#8220;Class Period&#8221;) may be eligible to seek recovery. The deadline to apply for lead plaintiff is <b><span class=\"xn-chron\">August 11, 2025<\/span>. <\/b>To learn your rights, <\/i><br \/>\n        <b><br \/>\n          <i><br \/>\n            <u><br \/>\n              <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4468695-1&amp;h=1157181372&amp;u=https%3A%2F%2Finvestigations.bergermontague.com%2Frocket-pharmaceuticals%2F&amp;a=CLICK+HERE\" target=\"_blank\" rel=\"nofollow\">CLICK HERE<\/a><br \/>\n            <\/u><br \/>\n          <\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i>.<\/i><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>About <span class=\"xn-person\">Berger Montague<\/span><br \/><\/b><br \/>\n        <span class=\"xn-person\">Berger Montague<\/span>, with offices in <span class=\"xn-location\">Philadelphia<\/span>, <span class=\"xn-location\">Minneapolis<\/span>, <span class=\"xn-location\">Delaware<\/span>, <span class=\"xn-location\">Washington, D.C.<\/span>, <span class=\"xn-location\">San Diego<\/span>, <span class=\"xn-location\">San Francisco<\/span> and <span class=\"xn-location\">Chicago<\/span>, has been a pioneer in <u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4468695-1&amp;h=1690873273&amp;u=https%3A%2F%2Fbergermontague.com%2Fsecurities%2F&amp;a=securities+class+action+litigation\" target=\"_blank\" rel=\"nofollow\">securities class action litigation<\/a><\/u> since its founding in 1970. <span class=\"xn-person\">Berger Montague<\/span> has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>For more information or to discuss your rights, please contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Andrew Abramowitz<\/span>, Senior Counsel<br \/><span class=\"xn-person\">Berger Montague<\/span><br \/>(215) 875-3015<br \/><a href=\"mailto:aabramowitz@bergermontague.com\" rel=\"nofollow\">aabramowitz@bergermontague.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Caitlin Adorni<\/span><br \/>\n        <br \/>\n        <span class=\"xn-person\">Berger Montague<\/span><br \/>\n        <br \/>(267) 764-4865<br \/><a href=\"mailto:cadorni@bergermontague.com\" rel=\"nofollow\">cadorni@bergermontague.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC30674&amp;sd=2025-07-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit-302505775.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit-302505775.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Berger Montague<\/span><\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC30674&amp;Transmission_Id=202507151606PR_NEWS_USPR_____DC30674&amp;DateId=20250715\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PHILADELPHIA , July 15, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc.(NASDAQ: RCKT) (&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;). The case was filed in the U.S. District Court for the District of New Jersey and alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program. Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, New Jersey, is a biotechnology company focused on developing gene therapies for rare diseases. The suit alleges that the Company failed to inform investors of a substantial protocol change, specifically the addition of a novel immunomodulatory agent, prior to a serious adverse &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-869967","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA , July 15, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc.(NASDAQ: RCKT) (&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;). The case was filed in the U.S. District Court for the District of New Jersey and alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program. Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, New Jersey, is a biotechnology company focused on developing gene therapies for rare diseases. The suit alleges that the Company failed to inform investors of a substantial protocol change, specifically the addition of a novel immunomodulatory agent, prior to a serious adverse &hellip; Continue reading &quot;ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T21:29:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit\",\"datePublished\":\"2025-07-15T21:29:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/\"},\"wordCount\":299,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/\",\"name\":\"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-07-15T21:29:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA , July 15, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc.(NASDAQ: RCKT) (&#8220;Rocket Pharmaceuticals&#8221; or the &#8220;Company&#8221;). The case was filed in the U.S. District Court for the District of New Jersey and alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program. Rocket Pharmaceuticals, headquartered in\u00a0Cranbury, New Jersey, is a biotechnology company focused on developing gene therapies for rare diseases. The suit alleges that the Company failed to inform investors of a substantial protocol change, specifically the addition of a novel immunomodulatory agent, prior to a serious adverse &hellip; Continue reading \"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-15T21:29:14+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit","datePublished":"2025-07-15T21:29:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/"},"wordCount":299,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/","name":"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-07-15T21:29:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-rckt-investors-contact-berger-montague-about-a-rocket-pharmaceuticals-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=869967"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869967\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=869967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=869967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=869967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}